INS and Hypoglycemia: These agents lower glucose through glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction, significantly decreasing the risk of hypoglycemia (13).In addition, dapagliflozin may be added to support weight loss and blood pressure control.